FXYD2

Across TCGA pan-cancer cohorts, FXYD2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of FXYD2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where FXYD2 RNA is repressed in tumor relative to normal tissue. In most cancer types FXYD2 is over-expressed in tumor, although a few such as KIRP and KIRC show the opposite, repressed pattern.

KIRP, KIRC, and UCEC are the cancer types where FXYD2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FXYD2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	Male	All	−1.705	<.001	11	view →
KIRC	Male	II,III,IV	−1.041	<.001	8	view →
UCEC	All	All	−0.435	<.001	6	view →
BRCA	All	III,IV	−0.347	<.001	6	view →
HNSC	All	II,III,IV	−0.580	.025	4	view →
BLCA	Female	All	−0.186	.002	4	view →
LUSC	All	II,III,IV	−0.183	.007	4	view →
CHOL	Female	All	+3.110	.001	2	view →
READ	All	All	−0.137	.009	2	view →
PRAD	All	All	−0.129	<.001	2	view →
COAD	All	III,IV	−0.090	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

FXYD2–KIRP

Open the KIRP breakdown →